MPS Loria Financial Planners LLC Purchases New Holdings in Hologic, Inc. $HOLX

MPS Loria Financial Planners LLC purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 3,101 shares of the medical equipment provider’s stock, valued at approximately $202,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Greenleaf Trust lifted its holdings in Hologic by 5.1% during the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock valued at $233,000 after buying an additional 173 shares in the last quarter. Beverly Hills Private Wealth LLC lifted its holdings in Hologic by 3.6% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock valued at $320,000 after buying an additional 180 shares in the last quarter. Allworth Financial LP lifted its holdings in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 216 shares in the last quarter. First American Bank lifted its holdings in Hologic by 0.9% during the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock valued at $1,870,000 after buying an additional 245 shares in the last quarter. Finally, SPC Financial Inc. lifted its holdings in Hologic by 2.2% during the 2nd quarter. SPC Financial Inc. now owns 12,859 shares of the medical equipment provider’s stock valued at $838,000 after buying an additional 278 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 2.0%

NASDAQ HOLX opened at $69.85 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company has a market capitalization of $15.54 billion, a price-to-earnings ratio of 28.98, a price-to-earnings-growth ratio of 2.35 and a beta of 0.63. The company’s 50-day simple moving average is $67.11 and its two-hundred day simple moving average is $63.51. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity

In other news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.88% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. Morgan Stanley lifted their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a report on Thursday, July 31st. Evercore ISI set a $78.00 price objective on shares of Hologic and gave the company an “outperform” rating in a report on Tuesday, October 7th. Argus lifted their price objective on shares of Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a report on Friday, September 19th. Finally, Stephens reiterated an “overweight” rating and set a $78.00 price objective on shares of Hologic in a report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Hologic has an average rating of “Moderate Buy” and an average target price of $80.15.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.